Juy-108 !link! Instant

A that potently and selectively inhibits both VEGFR‑2 and TIE2 can achieve continuous target suppression , provide patient convenience , and enable combination regimens with oral ICIs or targeted agents.

(Prepared April 10 2026 – all data current to the end of Q1 2026. Sources include peer‑reviewed publications, company filings, conference abstracts, and FDA/EMA public dossiers.) juy-108

Once I have a better understanding of your needs, I'll be happy to assist you in preparing your paper! A that potently and selectively inhibits both VEGFR‑2

| Modality | Pros | Cons | |---|---|---| | | High specificity, long half‑life | Limited tissue penetration, intravenous administration | | Bispecific antibodies (VEGFR‑2/TIE2) | Simultaneous blockade, long half‑life | Complex manufacturing, high cost | | Small‑molecule kinase inhibitors | Oral dosing, rapid tissue distribution (including CNS), tunable pharmacokinetics | Potential off‑target activity, resistance mutations | | Modality | Pros | Cons | |---|---|---|